Research Frontiers (REFR) Q3 2026 earnings review
Research Frontiers' supplier restarts production, but its cash shrinks
Research Frontiers, which licenses glass that darkens on command, earned almost nothing while its film supplier stood idle. Fee income fell 79% from a year ago. A one-time government royalty did not repeat, and Gauzy, the Israeli maker of the film, could not produce. By our math, the remaining cash covers roughly four months of spending.
| Fee income | $77,041 −79% from a year ago |
|---|---|
| Net loss | $510,304 $298,508 a year ago |
| Cash | $644,628 $1.13 million a year ago |
| Royalty outlook | New no material recovery until after the fourth quarter |
⚖️ Verdict: 🔴 Bearish
The story got worse, because the cash to wait for a restart is running out. The company's filing warns of "substantial doubt" that the business can keep going, and Gauzy owes all the royalties still due. The good news: Gauzy raised new money and has begun restarting its plants. But chief executive Joseph Harary expects no material royalty recovery before 2027.
The question now is whether Gauzy's film reaches customers before Research Frontiers needs new money. If Gauzy pays its debts soon, the company may avoid a share sale; if French courts delay payment, it will probably have to sell shares. Year-end cash and receivables will tell.
🐂 Bull Case
Gauzy Raised Money to Restart Film Production
Gauzy, an Israeli company, is the sole maker of the SPD film that Research Frontiers licenses. The film is a thin light-control layer that lets glass darken or clear when a user presses a switch. Gauzy ran short of cash late last year, so its plants stopped producing.
In October Gauzy restructured its debts and announced $7 million of new financing. Research Frontiers said that Gauzy's payments "have begun to support the restart of SPD emulsion production in Israel and SPD film production in Germany". Emulsion is the chemical that Gauzy coats onto the film.
"Our focus is shifting from managing an interruption in the availability of SPD light-control film, to supporting the return of supply, growth, and moving multiple commercial programs forward," chief executive Joseph Harary said. Yet licensees have not received any restarted film, and royalties arrive only after they build and sell products with it.
What to watch: the date Gauzy reports its first film shipments from Germany. Licensees cannot build products without film, so that date sets when royalties can start to return.
Aircraft Makers Keep Choosing SPD Windows
SPD-SmartGlass is the dimmable glass that Research Frontiers licenses. The licensor said aircraft makers chose it for windows "on two new aircraft models expected to be produced in North America". The glass also appeared on a new light jet unveiled in October.
Chief executive Joseph Harary added that his team started "a new program with a North American aircraft manufacturer" the day before the call. Royalties from helmet visors and ski goggles also rose, which softened the fall elsewhere.
These wins came while film supply was halted, so buyers picked SPD despite the risk. But aircraft programs take years to reach production, and none yet shows a revenue figure.
What to watch: whether Harary names the new aircraft maker or reports aircraft royalties in 2027. A named program with a production date would turn interest into income.
Positives this quarter didn't test
Several long-standing strengths of Research Frontiers still stand, but none showed up in fee income this quarter, because no film reached its licensees.
- Cadillac: chief executive Joseph Harary said he is "very encouraged" by the volumes GM's luxury brand quoted; production orders would move this.
- Four carmakers using SPD: Mercedes, Ferrari, Cadillac and McLaren kept their programs through the halt, Harary said; a new model would move this.
- Black SPD, a neutral-coloured version of the film: samples looked promising in 2026; customer approval would move this.
- Architectural retrofit, a kit that adds SPD to existing windows: the launch waits for film; first paid installations would move this.
🐻 Bear Case
Cash Now Covers About Four Months
Research Frontiers pays its bills from royalties and occasional share sales. Royalties have shrunk this year, and its quarterly filing warns of "substantial doubt" that it can keep operating for 12 months without new cash.
Cash fell to $644,628 at the end of September, down $443,328 in three months. By our math, that pace leaves about four months of spending, because the licensor sold no shares in the quarter.
- Legal fees: $66,814, against zero a year ago
- Marketing and investor relations: $20,759, down from $109,201
- Total expenses: down 10.3% from a year ago
Chief executive Joseph Harary said collections due in November and December "would alleviate or almost completely eliminate our need to raise additional funds". The balance sheet argues otherwise. Net royalties receivable total $223,853, well short of the quarter's outflow. The gross figure is $1.78 million, but Research Frontiers holds a reserve against 87% of it.
What to watch: cash and receivables at year-end, in the annual report due early next year. If cash falls again without Gauzy's payment, Research Frontiers will likely need to sell new shares.
Fee Income Fell 79% as Supply Stopped
Fee income is the royalty and licence money Research Frontiers earns from licensees' sales. It dropped to $77,041 in the third quarter, from $359,444 a year earlier. The company blamed a government royalty that did not repeat and the halt at Gauzy, without saying how large that royalty was.
- Nine-month fee income: down 71% from a year ago
- Change from the second quarter: down 11%
- Licensees above 10% of fee income: two, at about 40% each
Chief executive Joseph Harary said: "We do not expect a restart to produce a material royalty recovery until after the fourth quarter of 2026." No quarter of 2026 has topped $140,000 so far.
What to watch: first-quarter 2027 fee income, reported next spring. A clear rise would show that licensees are selling SPD products again.
Gauzy Now Owes All of the Royalties Due
Gauzy is more than Research Frontiers' film supplier. The Israeli group holds a licence, invests in the licensor, and its chief executive sits on the board. A French court placed its subsidiary Vision Systems in rehabilitation last year.
That dependence deepened this year. Gauzy and Vision Systems now account for all net royalties receivable, against 79% at the end of 2025. They also supplied 45% of nine-month fee income, up from 13%.
Chief executive Joseph Harary said the payments look likely in November and December, but a French tribunal sets that timetable. He also noted that part of Gauzy's new financing would go back, as Gauzy itself disclosed.
What to watch: the French appeal rulings on Vision Systems, which Harary said were due shortly. A win for Gauzy would give the supplier more money to pay what it owes.
Risks this quarter didn't answer
Four standing concerns got no new evidence this quarter, either because film supply stopped or because Research Frontiers gave no update on them.
- Nasdaq listing: the licensor no longer meets two Nasdaq rules, and chief executive Joseph Harary said it may apply for a hearing in December; a compliance plan would settle this.
- Slow car programs: no new car model reached production; a carmaker naming a production date would move this.
- Lost contests to rival smart-glass technologies: no update on head-to-head bids; a win against a rival would move this.
- Emulsion shipping from Israel, where Gauzy makes the chemical: last year's war disrupted it, and neither the release nor the call mentioned it; steady shipments to Germany would settle it.
👓 Other Themes
Harary Described a Second Way to Make Film
Chief executive Joseph Harary described a hybrid supply plan on the call. Under it, "a company like Gauzy makes the emulsion", the specialized chemical, and other firms coat it onto film. He said talks have taken place but named no partner. Building such a channel "is not instantaneous", Harary added.
💲 Other KPIs
Shareholders' equity, the gap between assets and liabilities, shrank to $612,789. It stood at $1.12 million in June and $1.50 million a year ago. Losses have used up the money from the February share sale. Chief executive Joseph Harary said the group does not meet Nasdaq's equity-based listing test.
Shares outstanding held at 34.9 million for a third straight quarter. That is 3.6% above a year ago, after the first-quarter share and warrant sale. Another 4.3 million options and warrants sit on top, and the quarterly filing says the licensor may need to raise more capital within 12 months.
Deferred revenue, fees licensees paid ahead of the period they cover, fell to $27,452 from $69,068 in June. The balance was zero at the end of 2025. So little prepaid income remains to support the next few quarters' fee income.
🔮 Guidance
New. Chief executive Joseph Harary said royalties will stay low through the fourth quarter and recover in a material way only in 2027 at the earliest. Licensees must first receive film, build products and sell them, so an autumn restart cannot lift this year. Research Frontiers gave no numeric outlook.
❓ Key Questions
How much of the money owed will Gauzy actually pay?
Research Frontiers holds a reserve against most of its gross royalties receivable, and Gauzy accounts for all of the net amount. A payment schedule would show whether the licensor can avoid selling new shares.
Will Research Frontiers raise money before royalties return?
Harary said any raise may be small, but one quarter's cash outflow already exceeds the net royalties owed to the company. Readers need the size and timing of any offering.
When will Gauzy ship its first restarted film?
Royalties begin only after licensees receive film and sell finished products. A shipment date from the German plant would anchor the 2027 recovery Harary describes.
How large was last year's government-contract royalty?
The company named it as a main cause of the fall in fee income but gave no figure. Without it, readers cannot tell how much of the decline came from the halt at Gauzy.
Will the company ask Nasdaq for a hearing?
The compliance period ends on November 30, and Harary said the board will decide in December. The choice decides whether Research Frontiers stays on Nasdaq.